Dopamine receptor supersensitivity: Development, mechanisms, presentation, and clinical applicability

Neurotoxicity Research

Volumn 14, Issue 2-3, 2008, Pages 121-128

  Kostrzewa, Richard M ^a   Kostrzewa, John P ^a   Brown, Russell W ^b   Nowak, Przemyslaw ^c   Brus, Ryszard ^c  

^a East Tennessee State University   (United States)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Denervation; Dopamine; Priming; Receptor supersensitivity; Serotonin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; HALOPERIDOL; OXIDOPAMINE; QUINPIROLE; SEROTONIN; 5,7 DIHYDROXYTRYPTAMINE; DOPAMINE 2 RECEPTOR; SEROTONIN RECEPTOR;

ADIPSIA; AKINESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; APHAGIA; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DENERVATION; DISEASE ASSOCIATION; HUMAN; MENTAL DISEASE; NERVE CELL; NEWBORN; NONHUMAN; PATHOPHYSIOLOGY; PERINATAL PERIOD; PHENOTYPE; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY; STRIATONIGRAL DEGENERATION; SUBSTANCE ABUSE; SUPERSENSITIVITY; AGE; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG POTENTIATION; PHYSIOLOGY; REVIEW;

RATTUS; RODENTIA;

5,7-DIHYDROXYTRYPTAMINE; AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; DENERVATION; OXIDOPAMINE; RATS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; STRIATONIGRAL DEGENERATION;

EID: 63249102846     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033804     Document Type: Article

References (63)

1. Baumgarten HG and L Lachenmayer (2004) Serotonin neuro-toxins - past and present. Neurotox. Res. 6(7-8), 589-614. Review.
2. Baumgarten HG, A Bjorklund, L Lachenmayer and A Nobin (1973) Evaluation of the effects of 5,7-dihydroxytryptamine on serotonin and catecholamine neurons in the rat CNS. Acta Physiol. Scand. Suppl. 391, 1-19.
3. Berger TW, S Kaul, EM Stricker and MJ Zigmond (1985) Hyperinnervation of the striatum by dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats. Brain Res. 336, 354-358.
4. Breese GR, AA Baumeister, TJ McCown, SG Emerick, GD Frye, K Crotty and RA Mueller (1984) Behavioural differences between neonatal and adult 6-hydroxydopaminetreated rats to dopamine agonists: Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J. Pharmacol. Exp. Ther. 231, 343-354.
5. Breese GR, AA Baumeister, TC Napier, GD Frye and RA Mueller (1985a) Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 235, 287-295.
6. Breese GR, TC Napier and RA Mueller (1985b) Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: Functional supersensitivity of D-1 dopamine receptors in neonatally-lesioned rats. J. Pharmacol. Exp. Ther. 234, 447-455.
7. 2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J. Pharmacol. Exp. Ther. 240, 167-176.
8. Breese GR, HE Criswell, GE Duncan and RA Mueller (1990) A dopamine deficiency model of Lesch-Nyhan disease - the neonatal-6-OHDA-lesioned rat. Brain Res. Bull. 25(3), 477-484. Review.
9. Breese GR, DJ Knapp, HE Criswell, SS Moy, ST Papadeas and BL Blake (2005) The neonate-6-hydroxydopamine-lesioned rat: A model for clinical neuroscience and neurobiological principles. Brain Res. Brain Res. Rev. 48, 57-73. Review.
10. Brus R, RM Kostrzewa, KW Perry and RW Fuller (1994) Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment. J. Pharmacol. Exp. Ther. 268, 231-237.
11. Brus R, A Plech and RM Kostrzewa (1995) Enhanced quinpirole responses in rats lesioned neonatally with 5,7-dihydroxytryptamine. Pharmacol. Biochem. Behav. 50, 649-653.
12. 2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats. Neurotox Res. 5, 329-338.
13. Costall B, RJ Naylor and JL Neumeyer (1975) Differences in the nature of the stereotyped behaviour induced by aporphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas. Eur. J. Pharmacol. 31, 1-16.
14. 1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats. J. Neurosci. 9, 125-133.
15. Descarries L, J-J Soghomonian, S Garcia, G Doucet and JP Bruno (1992) Ultrastructural analysis of the serotonin hyperinnervation in adult rat neostriatum following neonatal dopamine denervation with 6-hydroxydopamine. Brain Res. 569, 1-13.
16. 1 receptors in adult rat neostriatum after neonatal 6-hydroxydopamine denervation. Brain Res. 536, 287-296.
17. El Mansari M, F Radja, A Ferron, TA Reader, E Molina-Holgado and L Descarries (1994) Hypersensitivity to serotonin and its agonists in serotonin-hyperinnervated neostriatum after neonatal dopamine denervation. Eur. J. Pharmacol. 261, 171-178.
18. Gong L and RM Kostrzewa (1992) Supersensitized oral response to a serotonin agonist in neonatal 6-OHDA treated rats. Pharmacol. Biochem. Behav. 41, 621-623.
19. Gong L, RM Kostrzewa, RW Fuller and KW Perry (1992) Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. J. Pharmacol. Exp. Ther. 261, 1000-1007.
20. 1 receptors in neonatal 6-OHDA-lesioned rats. Dev. Brain Res. 76, 59-65.
21. Gong L, RM Kostrzewa, KW Perry and RW Fuller (1993b) Dose-related effects of a neonatal 6-OHDA lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Dev. Brain Res. 76, 233-238.
22. 1 receptor mRNA levels: Absence of other neurochemical associations with the enhanced behavioral responses of lesioned rats. J. Neurochem. 63, 1282-1290.
23. Huang NY and RM Kostrzewa (1994) Persistent oral dyskinesias in haloperidol-withdrawn neonatal 6-hydroxydopaminelesioned rats. Eur. J. Pharmacol. 271, 433-437.
24. 3H] raclopride binding to neostriatal homogenates. J. Pharmacol. Exp. Ther. 280, 268-276.
25. 1 dopamine agonists SKF 38393 and A 6890 in neonatal 6-hydroxydopamine-lesioned rats: Behavioral effects and induction of c-fos-like immunoreactivity. J. Pharmacol. Exp. Ther. 262, 855-865.
26. Jonsson G, C Pycock, K Fuxe and C Sachs (1974) Changes in the development of central noradrenaline neurons following neonatal administration of 6-hydroxydopamine. J. Neurochem. 22, 419-426.
27. Kostrzewa RM (1995) Dopamine receptor supersensitivity. Neurosci. Biobehav. Rev. 19, 1-17.
28. Kostrzewa RM and R Brus (1991) Ontogenic homologous supersensitization of quinpirole-induced yawning in rats. Pharmacol. Biochem. Behav. 39, 517-519.
29. Kostrzewa RM and RE Garey (1976) Effects of 6 hydroxydopa on noradrenergic neurons in developing rat brain. J. Pharmacol. Exp. Ther. 197, 105-118.
30. Kostrzewa RM and RE Garey (1977) Sprouting of noradrenergic terminals in rat cerebellum following neonatal treatment with 6 hydroxydopa. Brain Res. 124, 385-391.
31. 1 receptors mediate enhanced oral activity after neonatal 6-OHDA. Pharmacol. Biochem. Behav. 39, 677-682.
32. Kostrzewa RM and JW Harper (1974) Effects of 6 hydroxydopa on catecholamine-containing neurons in brains of newborn rats. Brain Res. 69, 174-181.
33. Kostrzewa RM and D Jacobowitz (1974) Pharmacological actions of 6-hydroxydopamine. Pharmacol. Rev. 26, 199-288.
34. Kostrzewa RM and D Neely (1993) Enhanced pilocarpineinduced oral activity responses in neonatal 6-OHDA-treated rats. Pharmacol. Biochem. Behav. 45, 737-740.
35. 2 receptors. Eur. J. Pharmacol. 183, 1411-1412.
36. Kostrzewa RM, R Brus and J Kalbfleisch (1991) Ontogenetic homologous sensitization to the antinociceptive action of quinpirole in rats. Eur. J. Pharmacol. 209, 157-161.
37. Kostrzewa RM, R Brus, KW Perry and RW Fuller (1993a) Age-dependence of a 6-hydroxydopamine lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Dev. Brain Res. 76, 87-93.
38. Kostrzewa RM, R Brus, M Rykaczewska and A Plech (1993b) Low dose quinpirole ontogenically sensitizes to quinpirole-induced yawning in rats. Pharmacol. Biochem. Behav. 44, 487-489.
39. Kostrzewa RM, J Guo and FP Kostrzewa (1993c) Ontogenetic quinpirole treatments induce vertical jumping activity in rats. Eur. J. Pharmacol. 239, 183-187.
40. Kostrzewa RM, R Brus, JH Kalbflesich, KW Perry and RW Fuller (1994) Proposed animal model of attention deficit hyperactivity disorder. Brain Res. Bull. 34, 161-167.
41. Kostrzewa RM, TA Reader and L Descarries (1998) Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain. J. Neurochem. 70, 889-898.
42. Luthman J, B Bolioli, T Tustsumi, A Verhofstad and G Jonsson (1987) Sprouting of striatal nerve terminals following selective lesion of nigro-striatal dopamine neurons in neonatal rat. Brain Res. Bull. 19, 269-274.
43. Molina-Holgado E, KM Dewar, L Descarries and TA Reader (1994) Altered dopamine and serotonin metabolism in the dopamine-denervated and serotonin-hyperinnervated neostriatum of adult rat after neonatal 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 270, 713-721.
44. Mrini A, J-P Soucy, F Lafaille, P Lemoine and L Descarries (1995) Quantification of the serotonin hyperinnervation in adult rat neostriatum after neonatal 6-hydroxydopamine lesion of nigral dopamine neurons. Brain Res. 779, 303-308.
45. Nowak P, R Brus and RM Kostrzewa (2001) Amphetamine-induced enhancement of neostriatal in vivo microdialysate dopamine content in rats, quinpirole-primed as neonates. Pol. J. Pharmacol. 53, 319-329.
46. Nowak P, L Labus, RM Kostrzewa and R Brus (2006) DSP-4 prevents dopamine receptor priming by quinpirole. Pharmacol. Biochem. Behav. 84, 3-7.
47. Okamura H, C Yokoyama and Y Ibata (1995) Lateromedial gradient of the susceptibility of midbrain dopaminergic neurons to neonatal 6-hydroxydopamine toxicity. Exp. Neurol. 136, 136-142.
48. OÑwi"cimska J, R Brus, R Szkilnik, P Nowak and RM Kostrzewa (2000) 7-OH-DPAT, unlike quinpirole, does not prime a yawning response in rats. Pharmacol. Biochem. Behav. 67, 11-15.
49. Palomo T, T Archer, RJ Beninger and RM Kostrzewa (2002) Neurodevelopmental liabilities of substance abuse. Neurotox. Res. 4, 267-279.
50. Plech A, R Brus, JH Kalbfleisch and RM Kostrzewa (1995) Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats. Psychopharmacology (Berl.) 119, 466-473.
51. 2 receptors in adult rat neostriatum after neonatal dopamine denervation: quantitative data from ligand binding, in situ hybridization and iontophoresis. Neuroscience 57, 635-648.
52. 2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: A quantitative autoradiographic study. Brain Res. 606, 273-285.
53. 1 stimulation. Life Sci. 19, 33, 2479-2482.
54. Shaywitz BA, JH Klopper and JW Gordon (1976a) Paradoxical response to amphetamine in developing rats treated with 6-hydroxydopamine. Nature 261, 153-155.
55. Shaywitz BA, RD Yager and JH Klopper (1976b) Selective brain dopamine depletion in developing rats: An experimental model of minimal brain dysfunction. Science 191, 305-308.
56. Snyder AM, MJ Zigmond and RD Lund (1986) Sprouting of serotonergic afferents into striatum after dopamine depleting lesions in infant rats: a retrograde transport and immunocytochemical study. J. Comp. Neurol. 245, 274-281.
57. Soucy JP, F Lafaille, P Lemoine, A Mrini and L Descarries (1994) Validation of the transporter ligand cyanoimipramine as a marker of serotonin innervation density in brain. J. Nucl. Med. 35, 1822-1830.
58. Szechtman H and EZ Woody (2006) Obsessive-compulsive disorder as a disturbance of security motivation: Constraints on comorbidity. Neurotox. Res. 10, 103-112.
59. Towle AG, HE Criswell, EH Maynard, JM Lauder, TH Joh, RA Mueller and GR Breese (1989) Serotonergic innervation of the rat caudate following a neonatal 6-hydroxydopamine lesion: An anatomical, biochemical and pharmacological study. Pharmacol. Biochem. Behav. 34, 367-374.
60. Ungerstedt U (1971a) Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367, 95.
61. Ungerstedt U (1971b) Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol. Scand. Suppl. 367, 69.
62. Ungerstedt U (1971c) Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol. Scand. Suppl. 367, 49-68.
63. Zigmond MJ and EM Stricker (1989) Animal models of parkinsonism using selective neurotoxins: Clinical and basic implications. Int. Rev. Neurobiol. 31, 1-79.